| Literature DB >> 33171936 |
Gianmaria Fabrizio Ferrazzano1,2, Cristina Papa1, Antonino Pollio3, Aniello Ingenito1, Giancarla Sangianantoni1, Tiziana Cantile1.
Abstract
In the scenario of promising sources of functional foods and preventive drugs, microalgae and cyanobacteria are attracting global attention. In this review, the current and future role of microalgae as natural sources of functional foods for human health and, in particular, for oral health has been reported and discussed in order to provide an overview on the state of art on microalgal effects on human oral health. It is well known that due to their richness in high-valuable products, microalgae offer good anti-inflammatory, antioxidant, antitumoral, anti-glycemic, cholesterol-lowering, and antimicrobial activity. Moreover, the findings of the present research show that microalgae could also have a significant impact on oral health: several studies agree on the potential application of microalgae for oral cancer prevention as well as for the treatment of chronic periodontitis and different oral diseases with microbial origin. Thus, beneficial effects of microalgae could be implemented in different medical fields. Microalgae and cyanobacteria could represent a potential natural alternative to antibiotic, antiviral, or antimycotic therapies, as well as a good supplement for the prevention and co-adjuvant treatment of different oral diseases. Nevertheless, more studies are required to identify strains of interest, increase overall functioning, and make safe, effective products available for the whole population.Entities:
Keywords: Chlorella vulgaris; Spirulina platensis; Streptococcus mutans; antimicrobial activity; microalgae; oral health
Mesh:
Substances:
Year: 2020 PMID: 33171936 PMCID: PMC7664199 DOI: 10.3390/molecules25215164
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Application of microalgae in different fields.
Different actions of S. platensis on human health and related bibliographical references.
| Ref. | |
|---|---|
| Highly nutrient | [ |
| Immunostimulating | [ |
| Antiviral | [ |
| Antimicotic | [ |
| Anti-cancer | [ |
| Antioxidant | [ |
| Skin-beneficial | [ |
Different actions of Chlorella sp. on human health and related bibliographical references.
| Ref. | |
|---|---|
| Anti-cancer | [ |
| Antioxidant | [ |
| Anti-inflammatory | [ |
| Antibacterial, antimicotic | [ |
Effects of cyanobacteria and microalgae on oral health: outcomes of the examined in vitro/in vivo studies, potential therapeutic applications, and related bibliographic references.
| Species/Source | Type of Study | Results | Potential Application | Ref. |
|---|---|---|---|---|
| In vitro | Inhibition of HSV-1, Kaposi sarcoma-associated herpes virus, and human herpes virus 8. | Prophylactic treatment of herpes viruses infections. | [ | |
|
| In vivo | Complete regression of precancerous lesions in 45% of subjects. | Chemopreventive therapy for tobacco-induced oral leucoplakia. | [ |
| Astaxanthin | In vitro | Decrease of IL-6 and TNF-α and increase of cell proliferation in oral lichen planus. | Anti-inflammatory treatment for oral lichen planus. | [ |
| Astaxanthin | In vivo | Decrease of the incidence of oral pre-neoplastic lesions and cell proliferation activity in rats after 8 weeks of treatment. | Prevention of 4-NQO-induced tongue carcinogenesis. | [ |
|
| In vivo | Decrease of dysplastic changes on hamsters’ buccal pouch after 14 weeks of treatment. | Oral cancer preventive therapy. | [ |
| In vivo | Inhibition of JAK-2/STAT-3 downstream events in hamster buccal pouch tumor progression. | Oral cancer therapy. | [ | |
| GM15 peptide from | In vitro | Scavenge of superoxide and hydroxyl radicals and reduction of intracellular oxidative stress. | Antioxidant treatment for oral cancer. | [ |
| FAME extracted from | In vitro | Inhibition of | Antimicrobial therapy against Gram-positive bacteria, Gram-negative bacteria, and fungi. | [ |
| In vitro | Inhibition of | Antibiotics and fungicides. | [ | |
| Acetone extracts of | In vitro | Inhibition | Antibiotic and fungicide. | [ |
| Ethanol extracts of | In vitro | Inhibition of | Antibiotic. | [ |
| Extract of | In vitro | Inhibition of | Antibiotic. | [ |
| Extract of | In vitro | Inhibition of | Fungicides. | [ |
| Silver nanoparticles biosynthesized from | In vitro | Inhibition of | Antibiotic. | [ |
| Locally derived | In vivo | Beneficials in the treatment of chronic periodontitis. | Co-adjuvant in the non-surgical treatment of periodontitis. | [ |
| Systemic astaxanthin administration | In vivo | Reduction of alveolar bone loss in ligature-induced periodontitis in rats. | Treatment of periodontitis. | [ |
| Cyp, an | In vitro | Inhibition of TNF-α, IL-1β, and IL-8 expression. | Treatment of periodontitis. | [ |
| Systemic | In vivo | Significant improvement in oral submucous fibrosis symptoms after 3 months of therapy. | Adjuvant therapy in the management of oral submucous fibrosis. | [ |
| Systemic | In vivo | Highly significant clinical improvements in oral submucous fibrosis after 3 months of therapy. | Adjuvant therapy in the management of oral submucous fibrosis. | [ |
| Astaxanthin | In vivo | Increase of saliva flow after 72 weeks of treatment. | Hyposalivation treatment. | [ |
| Astaxanthin | In vitro and in vivo | Increase of saliva flow and decrease of oxidative stress markers. | Hyposalivation treatment. | [ |
| In vivo | Increase of saliva flow in subjects with lower levels of saliva secretion. | Hyposalivation treatment. | [ | |
| In vivo | Reduction of Hg++, Ag, Sn, and Pb in subjects with long-term titanium dental implants and/or amalgam fillings. | Heavy metal detoxyfing agents. | [ | |
| Sodium alendronate incorporated into biosilica shells of cultured | In vitro | Decrease of metabolic activity of J774 osteoclast-like cells. | Drug-carrier for bifosphonates. | [ |